Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

And that's every four-week dosing, we expect that enhancement to the label second half of this year and there's also RVO. So RVO is about 20% of the EYLEA business right now. And having that ...

Ocular Therapeutix (NASDAQ:OCUL) stock rises as Needham rates the company a new Buy, citing the potential of its lead candidate, Axpaxli. Read more here.

Kodiak reports completing patient enrollment in its late-stage study evaluating tarcocimab for diabetic retinopathy.

Eylea has been one of Regeneron's top growth ... Regeneron and Sanofi are also seeking a label expansion for Dupixent in treating a rare skin disease called bullous pemphigoid.

EVP Marion McCourt responded that EYLEA HD's profile, including durability and potential label enhancements, strengthens its competitive position. Tyler Van Buren, TD Cowen: Asked about the timing ...

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Fresh off a label expansion in treating COPD last year ... So, Dupixent will help Regeneron make up some of the Eylea-related losses. Third, Regeneron has a deep pipeline and is especially ...